Bioaffinity Technologies, Inc. · NASDAQ:BIAF
Bioaffinity Technologies — 8th Annual Dawson James Small Cap Growth Conference 2023
16 slides from Bioaffinity Technologies's conference presentation, Oct 10, 2023
Slide 1: bioAffinity Technologies - Dawson James Small Cap Growth Conference
‘October 2023 e e e e e bidAffinity TECHNOLOGIES NASDAQ: BIAF / BIAFW 8h Annual Dawson James Small Cap Growth Conference October 12, 2023
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation and statements by management or other persons acting by or on behalf of bioAffinity Technologies made in connection with this presentation constitute "forward-looking statements” within the meaning of the sa
Slide 3: Investment Highlights
Investment Highlights CyPath Lung is an accurate, non-invasive test for early detection of lung cancer Patient-friendly At-home collection (no needles, no blood) with results to physician 3 days after sample arrives at the lab 92% 87% 99% Sensitivity’ Specifi Negative Predictive Value High specifici
Slide 4: Market Opportunity: The Need for Early Lung Cancer Detection
Market Opportunity: The Need for Early Lung Cancer Detection Lae I Most patients currently are 7 t diagnosed with late-stage (Stages IlIl-lV) lung cancer when the survival rate is low Accurate, early cancer detection can v Increase long-term survival v Reduce unnecessary invasive procedures v Improv
Slide 5: Physician-Focused, Patient-Friendly Market Opportunity
Physician-Focused, Patient-Friendly Market Opportunity More Accurate Diagnosis / Fewer Unnecessary, Invasive Procedures @ clinic @home @ laboratory @ clinic > eae ships overnight a a ci Patients complete a Aldriven automated data Physician receives results Physician orders 3-day sputum analysis of f
Slide 6: Impactful Branding
Impactful Branding Well-tested Brand Strategy being rolled out: v Articulates a clear, simple message v Acknowledges the clinical need v Highlights competitive advantages CyPath Lung THE NODULE WAS INDETERMINATE. BUT YOU CAN'T TREAT INDETERMINATE. INTRODUCING CyPath Lung KNOW MORE. MOVE FORWARD.
Slide 7: Market Testing: Lessons Learned
Market Testing: Lessons Learned CyPath Lung ~~ OReimbursement is Essential OPublications are Powerful Ses Sete a OBrand Awareness is Key trroouciInc CyPathLung KNOW MORE. MOVE FORWARD, Q Sales Driven by Reps + Multi-Media
Slide 8: Market Testing: Lessons Addressed
Market Testing: Lessons Addressed Q Reimbursement is Essential Y Specific CPT code for CyPath® Lung effective October 1, 2023 ¥_ CMS decision November 2023 on allowable Medicare reimbursement with effective date January 1, 2024 ¥ Precision fee schedule = $1900 test reimbursement 87%. Specificity 92h
Slide 9: CyPath Lung: Comparison to Current Standard of Care
CyPath Lung Comparison to Current Standard of Care for Follow-up after Positive LDCT Lung Cancer Diagnostic Procedure or Test Sensitivity Specificity CyPath Lung 92% 87% (individuals at high risk with nodules <20mm) FDG PET imaging (individuals with suspicious lung nodules) 89% 75% Bronchoscopy (ind
Slide 10: Revealing the Lung Microenvironment with AI-driven Flow Cytometry
CyPath Lung Revealing the Lung Microenvironment with Al-driven Flow Cytometry Advanced flow cytometry interrogates millions of cells in minutes Reveals cell populations residing in the lung micro-environment (sputum) by labelling cancer and cancer- related cells with TCPP, our specific porphyrin tha
Slide 11: Benefits of Precision Pathology Laboratory Acquisition
Benefits of Precision Pathology Laboratory Acquisition September 18, 2023 Increases Revenues v Captures CyPath® Lung full revenues v Adds Precision revenues to consolidated financials v Accretive in 2023; 100% return on cash investment expected in 24 months Adds Resources v Integrates operations and
Slide 12: Recent and Anticipated Milestones
bioAffinity Technologies Recent and Anticipated Milestones CFO Mike Dougherty joins team from Amazon CyPath® Lung CyPath® Lung- : pilot sales & specific CPT code effective CyPath® COPD clinical proof-of- concept trial opens JA Precision Pathology Laboratory Q3,2023, Q4.2023, Q1.2024. Q2.2024. Q3,/,.
Slide 13: Management
Management Innovative, Experienced, Dedicated Xavier Reveles Maria Zannes, JD Michael Dougherty, Vivienne Rebel, MD, PhD V e Founder, President MBA, CPA EVP, Chief Science & Chief Operating & CEO Vice President & CFO Medical Officer Officer 30+ years as C-suite 20+ years of experience in 20+ years a
Slide 14: Board of Directors
Board of Directors Decades of Successful Leadership from Start-Ups to Global Corporations Steve Girgenti Robert Anderson Stuart Diamond Roby Joyce, MD Executive Chairman Director Director Director ealthcare r executive positions at CIBA ‘estmeni Pharmaceutical Co, Becton Dickinson, ¢o' jor mor nmedi
Slide 15: Investment Recap
Investment Recap CyPath Lung is an accurate, non-invasive test for early detection of lung cancer Patient-friendly At-home collection (no needles, no blood) with results to physician 3 days after sample arrives at the lab 92% 87% 99% Sensitivity’ Specifi Negative Predictive Value High specificity an
Slide 16: For More Information
For More Information Company Contact: bioAffinity Technologies, Inc. 22211 West Interstate 10, Suite 1206 San Antonio, TX 78257 T: 210-698-5334 info@bioaffinitytech.com Investor Relations: Julie Anne Overton, Director of Communications jao@bioaffinitytech.com Tirth Patel, LHA Investor Relations tpat
bioAffinity Technologies — 8th Annual Dawson James Small Cap Growth Conference 2023 on 6ix